Skip to main content
SpringerLink
Log in

Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405

    Article  PubMed  CAS  Google Scholar 

  3. Avni B, Koren-Michowitz M (2011) Myeloid sarcoma: current approach and therapeutic options. Ther Adv Hematol 2:309–316

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Steensma DP, Friday BB (2007) Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy. Leuk Lymphoma 48(8):1628–1629

    Article  PubMed  CAS  Google Scholar 

  5. Singh SN, Cao Q, Gojo I, Rapoport AP, Akpek G (2012) Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT. Bone Marrow Transplant 47(7):1008–1009

    Article  PubMed  CAS  Google Scholar 

  6. Gornicec M, Wölfler A, Stanzel S, Sill H, Zebisch A (2017) Evidence for a role of decitabine in the treatment of myeloid sarcoma. Ann Hematol 96(3):505–506

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Ospedale degli Infermi, Biella, Italy

    Andrea Castelli, M. L. Mosca-Siez, P. Riccomagno & A. Conconi

  2. Department of Hematology, Ospedale Maggiore della Carità, Novara, Italy

    A. Patriarca

  3. Pathology Service, Ospedale degli Infermi, Biella, Italy

    D. Liscia

Authors
  1. Andrea Castelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. L. Mosca-Siez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Riccomagno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Patriarca
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Liscia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Conconi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Castelli.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castelli, A., Mosca-Siez, M.L., Riccomagno, P. et al. Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report. Ann Hematol 97, 1485–1486 (2018). https://doi.org/10.1007/s00277-018-3314-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3314-9

Search

Navigation